Toleikis Lars, Frenzel André
Protein Engineering and Antibody Technologies NBE Technologies, Merck Serono, Merck KGaA, Darmstadt, Germany.
Methods Mol Biol. 2012;907:59-71. doi: 10.1007/978-1-61779-974-7_3.
Despite the rising impact of the generation of antibodies by phage display and other technologies, hybridoma technology still provides a valuable tool for the generation of high-affinity binders against different targets. But there exist several limitations of using hybridoma-derived antibodies. The source of the hybridoma clones are mostly rat or mouse B-lymphocytes. Therefore a human-anti-mouse or human-anti-rat antibody response may result in immunogenicity of these antibodies. This leads to the necessity of humanization of these antibodies where the knowledge of the amino acid sequence of the proteins is inalienable. Furthermore, additional in vitro modifications, e.g., affinity maturation or fusion to other proteins, are dependent on cloning of the antigen-binding domains.Here we describe the isolation of RNA from hybridoma cells and the primers that can be used for the amplification of VL and VH as well as the cloning of the antibody in scFv format and its expression in Escherichia coli.
尽管噬菌体展示和其他技术在抗体生成方面的影响日益增大,但杂交瘤技术仍然是生成针对不同靶标的高亲和力结合物的宝贵工具。但是使用杂交瘤衍生抗体存在一些局限性。杂交瘤克隆的来源大多是大鼠或小鼠B淋巴细胞。因此,人抗小鼠或人抗大鼠抗体反应可能导致这些抗体具有免疫原性。这就使得在必须了解蛋白质氨基酸序列的情况下对这些抗体进行人源化成为必要。此外,额外的体外修饰,例如亲和力成熟或与其他蛋白质融合,依赖于抗原结合域的克隆。在此,我们描述了从杂交瘤细胞中分离RNA以及可用于扩增VL和VH的引物,以及以单链抗体片段(scFv)形式克隆抗体并在大肠杆菌中表达的方法。